Mark Puder

Credentials: · · · · ·

History

A 90 Day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome Who Are Dependent on Parenteral Nutrition
Food and Drug Administration · R01
Contact PI · $2M · Boston Children's Hospital
2021–2028
Cholestasis Reversal (Phase Ll): Efficacy of lV Fish Oil
Food and Drug Administration · R01
Contact PI · $801.5K · Boston Children's Hospital
2008–2013
Cholestasis Prevention: Efficacy of IV Fish Oil
Food and Drug Administration · R01
Contact PI · $359K · Boston Children's Hospital
2008–2012
Mechanisms of Hepatic Steatosis Prevention
National Institute of Diabetes and Digestive and Kidney Diseases · K08
Contact PI · $639.5K · Boston Children's Hospital
2005–2010

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
Principal investigator · Enrolling by invitation
Boston Children's Hospital
2022–2027
Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients
Principal investigator · Suspended
Boston Children's Hospital
2020–2027
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
Principal investigator · Recruiting
Boston Children's Hospital
2018–2028
Cholestasis Prevention: Efficacy of IV Fish Oil
Principal investigator · Completed · Phase 1
Boston Children's Hospital
2007–2011